Get started
Author

Christoph Matthias Ahlers

Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
2015 · Scott N. Gettinger, Leora Horn, et al. · Journal of Clinical Oncology · 1,178
PDF
First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70
2015 · Taofeek Kunle Owonikoko, Arif Hussain, et al. · Cancer Chemotherapy and Pharmacology · 88
Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. NIAID AIDS Clinical Trials Group.
1993 · B J Dezube, A B Pardee, et al. · PubMed · 87
Survival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC).
2013 · Julie R. Brahmer, Leora Horn, et al. · Journal of Clinical Oncology · 74
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)
2023 · Sophie Postel-Vinay, Vincent K Lam, et al. · Journal for ImmunoTherapy of Cancer · 71
PDF
A first-in-human, phase I study of an oral hedgehog (HH) pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors.
2010 · L. L. Siu, K. Papadopoulos, et al. · Journal of Clinical Oncology · 63
A Tat-induced auto-up-regulatory loop for superactivation of the human immunodeficiency virus type 1 promoter
1995 · D K Biswas, T R Salas, et al. · Journal of Virology · 52
Pentoxifylline inhibits HIV-1 LTR-driven gene expression by blocking NF-kappa B action.
1993 · D K Biswas, B J Dezube, et al. · PubMed · 52
Cytokine dysregulation in AIDS: in vivo overexpression of mRNA of tumor necrosis factor-alpha and its correlation with that of the inflammatory cytokine GRO.
1992 · B J Dezube, A B Pardee, et al. · PubMed · 52
High-Dose Pentoxifylline in Patients with AIDS: Inhibition of Tumor Necrosis Factor Production
1995 · B. J. Dezube, M. M. Lederman, et al. · The Journal of Infectious Diseases · 51
Cooperative inhibition of NF-kappa B and Tat-induced superactivation of human immunodeficiency virus type 1 long terminal repeat.
1993 · D K Biswas, C M Ahlers, et al. · Proceedings of the National Academy of Sciences · 44
Pentoxifylline and Other Protein Kinase C Inhibitors Down-Regulate HIV-LTR NF-κB Induced Gene Expression
1994 · Debajit K. Biswas, Christoph M. Ahlers, et al. · Molecular Medicine · 41
PDF
Belantamab Mafodotin in Combination with Novel Agents in Relapsed/refractory Multiple Myeloma: DREAMM-5 Study Design
2021 · Ajay K Nooka, Katja Weisel, et al. · Future Oncology · 36
Abstract CT150: A first-in-human phase I study of the OX40 agonist GSK3174998 (GSK998) +/- pembrolizumab in patients (Pts) with selected advanced solid tumors (ENGAGE-1)
2020 · Sophie Postel-Vinay, Vincent K. Lam, et al. · Cancer Research · 33
Cyclosporin A inhibits Ca2+‐mediated upregulation of the DNA repair enzyme DNA polymerase β in human peripheral blood mononuclear cells
1999 · Christoph Ahlers, Stefan Kreideweiß, et al. · European Journal of Biochemistry · 32
PDF
Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival
2008 · Erin R. Gardner, Christoph M. Ahlers, et al. · British Journal of Urology · 31
A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors
2014 · P. P. Peethambaram, L. C. Hartmann, et al. · Investigational New Drugs · 27
A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
2025 · Geoffrey Ku, Lin Shen, et al. · Clinical Cancer Research · 24
PDF
Ca2+‐induced p38/SAPK signalling inhibited by the immunosuppressant cyclosporin A in human peripheral blood mononuclear cells
1999 · Stefan Kreideweiß, Christoph Ahlers, et al. · European Journal of Biochemistry · 20
PDF
Phase II trial of cediranib (AZD2171) in docetaxel-resistant, castrate-resistant prostate cancer (CRPC)
2008 · J. J. Karakunnel, J. L. Gulley, et al. · Journal of Clinical Oncology · 17
ENGAGE-1: A first in human study of the OX40 agonist GSK3174998 alone and in combination with pembrolizumab in patients with advanced solid tumors.
2016 · Jeffrey R. Infante, Christoph M Ahlers, et al. · Journal of Clinical Oncology · 16
Abstract A55: A first-in-human, phase I study of an oral hedgehog pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors
2009 · Lillian L. Siu, Kyriakos P. Papadopoulos, et al. · Molecular Cancer Therapeutics · 16
ETS-TMPRSS2 fusion gene products in prostate cancer
2006 · Christoph M. Ahlers, William Figg, II · Cancer Biology & Therapy · 16
PDF
A phase 1 multicenter open-label dose-escalation study of BMS-936561 (MDX-1203) in clear cell renal cell carcinoma (ccRCC) and B-cell non Hodgkin lymphoma (B-NHL).
2014 · Taofeek Kunle Owonikoko, Arif Hussain, et al. · Journal of Clinical Oncology · 13
Inhibitory Effect of Ketoconazole on the Pharmacokinetics of a Multireceptor Tyrosine Kinase Inhibitor BMS‐690514 in Healthy Participants: Assessing the Mechanism of the Interaction With Physiologically‐Based Pharmacokinetic Simulations
2012 · Zheng Yang, Blisse Vakkalagadda, et al. · The Journal of Clinical Pharmacology · 13
Works count: 69
Citation count: 2,260
H-index: 19
I10-index: 28
Year
Topic
Type